论文部分内容阅读
目的:观察西格列汀联合甘精胰岛素对2型糖尿病患者血糖水平的影响,以及临床疗效和安全性。方法:66例2型糖尿病患者随机分为观察组和对照组,分别给予西格列汀联合甘精胰岛素治疗和预混胰岛素治疗3个月。比较两组患者治疗前后的血糖水平变化,以及血压血脂等指标变化。评价两组临床疗效和药品不良反应。结果:除低血糖AUC外,观察组患者治疗后的空腹血糖、餐后2 h血糖、糖化血红蛋白,以及72 h内平均血糖水平、血糖水平标准差、日内血糖平均波动幅度、日内血糖平均绝对差、日内血糖波动次数、高血糖AUC等血糖指标均较前明显改善(P<0.05),且优于对照组(P<0.05)。两组患者治疗前后血压、血脂无显著变化(P>0.05),观察组治疗后BMI低于对照组(P<0.05)。两组总有效率比较差异无统计学意义(P>0.05)。观察组药品不良反应发生率显著低于对照组(P<0.05)。结论:西格列汀联合甘精胰岛素能显著降低2型糖尿病患者的血糖水平,疗效确切,安全性高,建议临床推广。
Objective: To observe the effect of sitagliptin and insulin glargine on type 2 diabetes in patients with blood glucose levels, and clinical efficacy and safety. Methods: Sixty-six patients with type 2 diabetes were randomly divided into observation group and control group, and were treated with sitagliptin and insulin glargine and premixed insulin for 3 months respectively. The changes of blood glucose level before and after treatment, blood pressure, blood lipid and other indexes were compared between the two groups. Evaluation of two groups of clinical efficacy and adverse drug reactions. Results: In addition to the hypoglycemic AUC, the fasting blood glucose, postprandial 2-hour postprandial blood glucose, glycosylated hemoglobin, mean blood glucose level within 72 h, standard deviation of blood glucose level, mean daily blood glucose fluctuation, mean absolute difference of intra-day blood glucose (P <0.05), and better than the control group (P <0.05). Before and after treatment, there was no significant change in blood pressure and blood lipids in both groups (P> 0.05). The BMI in the observation group was lower than that in the control group after treatment (P <0.05). The total effective rate was no significant difference between the two groups (P> 0.05). The incidence of adverse drug reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Sogliptin combined with insulin glargine can significantly reduce blood glucose levels in patients with type 2 diabetes, the exact effect, high safety, the proposed clinical promotion.